Stocks and Investing Stocks and Investing
Tue, December 16, 2014
Mon, December 15, 2014
Fri, December 12, 2014
Thu, December 11, 2014
Wed, December 10, 2014
Tue, December 9, 2014
Mon, December 8, 2014
Fri, December 5, 2014
Thu, December 4, 2014
Wed, December 3, 2014
Tue, December 2, 2014
Mon, December 1, 2014
Fri, November 28, 2014
Wed, November 26, 2014
Tue, November 25, 2014
Mon, November 24, 2014
Fri, November 21, 2014
Thu, November 20, 2014
Wed, November 19, 2014

Evan Seigerman Maintained (BIIB) at Buy with Decreased Target to $400 on, Nov 19th, 2014


Published on 2024-10-25 06:42:07 - WOPRAI, Evan Seigerman
  Print publication without navigation


Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $425 to $400 on, Nov 19th, 2014.

Evan has made no other calls on BIIB in the last 4 months.



There are 3 other peers that have a rating on BIIB. Out of the 3 peers that are also analyzing BIIB, 0 agree with Evan's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Evan


  • Brian Skorney of "Baird" Upgraded from Hold to Buy on, Wednesday, October 22nd, 2014
  • Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $424 on, Thursday, July 24th, 2014
  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $430 on, Thursday, July 24th, 2014